1 |
Žučenka, Andrius; Vasilevska, Dominika; Daukėlaitė, Guoda; Trociukas, Igoris; Pečeliūnas, Valdas; Pileckytė, Regina; Griškevičius, Laimonas. Gilteritinib maintenance after allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia // HemaSphere: 28th Congress of the European Hematology Association EHA2023, June 8 - 15, Frankfurt, 2023 : abstract book. Philadelphia : Ovid Technologies (Wolters Kluwer Health). eISSN 2572-9241. 2023, vol. 7, suppl. 3, p. 1013-1014. DOI: 10.1097/01.HS9.0000969204.07443.aa. [DB: PubMed Central, Dimensions] |
2 |
Žučenka, Andrius; Čepulytė, Rūta; Davainienė, Birutė; Vasilevska, Dominika; Pileckytė, Regina; Trociukas, Igoris; Pečeliūnas, Valdas; Griškevičius, Laimonas. Azacitidine in combination with 14-day venetoclax versus azacitidine monotherapy for myelodysplastic syndrome with increased blasts-2 in clinical practice setting // HemaSphere: 28th Congress of the European Hematology Association EHA2023, June 8 - 15, Frankfurt, 2023 : abstract book. Philadelphia : Wolters Kluwer Health, Inc. eISSN 2572-9241. 2023, vol. 7, suppl. 3, art. no. PB2005, p. 3860-3861. DOI: 10.1097/01.HS9.0000974836.00135.ea. [DB: Dimensions] |
3 |
Daukėlaitė, Guoda; Vasilevska, Dominika; Vaitekėnaitė, Vilmantė; Trociukas, Igoris; Pileckytė, Regina; Griškevičius, Laimonas; Žučenka, Andrius. Venetoclax in combination with low-dose cytarabine and/or actinomycin D in relapsed or Refractory (R/R) acute myeloid leukemia (AML) patients with IDH1 or IDH2 mutations // Clinical lymphoma, myeloma & leukemia: Proceedings of the Society of Hematologic Oncology 2023 annual meeting. Dallas, TX : CIG Media Group. ISSN 2152-2650. eISSN 2152-2669. 2023, vol. 23, suppl. 1, art. no. AML-377, p. S293. DOI: 10.1016/S2152-2650(23)01047-9. [IF: 2.700; AIF: 5.000; Q2 (2023 InCities JCR SCIE)] |
4 |
Vasilevska, Dominika; Daukėlaitė, Guoda; Trociukas, Igoris; Pileckytė, Regina; Griškevičius, Laimonas; Žučenka, Andrius. Sequential allogeneic stem cell transplantation (alloSCT) after venetoclax (Ven)-based therapy for relapsed or refractory acute myeloid leukemia (R/R AML) or myelodysplastic syndrome with excess blasts 2 (MDS-EB2) // Clinical lymphoma, myeloma & leukemia: Proceedings of the Society of Hematologic Oncology 2023 annual meeting. Dallas, TX : CIG Media Group. ISSN 2152-2650. eISSN 2152-2669. 2023, vol. 23, suppl. 1, art. no. AML-519, p. S309. DOI: 10.1016/S2152-2650(23)01075-3. [IF: 2.700; AIF: 5.000; Q2 (2023 InCities JCR SCIE)] |
5 |
Davainienė, Birutė; Čepulytė, Rūta; Trociukas, Igoris; Pileckytė, Regina; Griškevičius, Laimonas; Žučenka, Andrius. Azacitidine in combination with venetoclax for myelodysplastic syndrome (MDS) with increased blasts-2 in clinical practice setting // Clinical lymphoma, myeloma & leukemia: Proceedings of the Society of Hematologic Oncology 2023 annual meeting. Dallas, TX : CIG Media Group. ISSN 2152-2650. eISSN 2152-2669. 2023, vol. 23, suppl. 1, art. no. AML-299, p. S287. DOI: 10.1016/S2152-2650(23)01033-9. [IF: 2.700; AIF: 5.000; Q2 (2023 InCities JCR SCIE)] |
6 |
Žučenka, Andrius; Davainienė, Birutė; Vaitekėnaitė, Vilmantė; Čepulytė, Rūta; Davainis, Linas; Daukėlaitė, Guoda; Kevličius, Lukas; Pileckytė, Regina; Trociukas, Igoris; Griškevičius, Laimonas. Real-world comparison of Venetoclax-based treatment versus intensive chemotherapy as bridging to allogeneic stem cell transplantation in MDS-IB2 patients // Blood: 65th ASH annual meeting abstracts. Washington : The American Society of Hematology. Published by Elsevier Inc. ISSN 0006-4971. eISSN 1528-0020. 2023, vol. 142, suppl. 1, p. 6474. DOI: 10.1182/blood-2023-178611. [DB: Science Citation Index Expanded (Web of Science)] [IF: 21.100; AIF: 5.000; Q1 (2023 InCities JCR SCIE)] |